The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need ...

The findings were in line with those of a large retrospective cohort study that showed that patients treated with GLP-1 ...

Novo Nordisk will explore how GLP-1 drugs potentially could help patients struggling with addiction, its head of development ...

Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

South Africa's Aspen Pharmacare has started registering GLP-1 drugs used to treat diabetes and obesity in markets where ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

How should you guide patients on GLP-1 therapy who are planning pregnancy? Dr Almandoz breaks down when to stop treatment, ...

GLP-1 medications like Ozempic are reshaping the way people snack, with fewer ultra-processed foods and a shift toward nutrient-packed bites. See what’s in and what’s out.